Cargando…
The Assessment of Response to Adjuvant Chemotherapy with CMF in Triple Negative Breast Cancer
INTRODUCTION: Breast cancers are divided into at least 4 sub Types on the Basis of gene expression profiles and expression of receptors as measured by IHC (Immunohistochemical). Triple negative breast cancer (TNBC) is more chemosensitive yet. It is much harder to detect than other sub types. At pres...
Autores principales: | Mousavi, Seyyed AsadoLah, Mashhadi, Efat, Iravani, Masud, Ghavamzade, Ardeshir |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Tehran University of Medical Sciences
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3913128/ https://www.ncbi.nlm.nih.gov/pubmed/24505513 |
Ejemplares similares
-
BCL2 is a predictive marker of adjuvant CMF regimen in triple-negative breast cancer patients
por: Bouchalova, K, et al.
Publicado: (2011) -
A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer
por: De Placido, S, et al.
Publicado: (2005) -
Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF
por: Poikonen, P, et al.
Publicado: (1999) -
Block sequential adriamycin CMF – optimal non-myeloablative chemotherapy for high risk adjuvant breast cancer?
por: Cameron, D A, et al.
Publicado: (2002) -
Subclinical cardiotoxicity following adjuvant dose-escalated FEC, high-dose chemotherapy, or CMF in breast cancer
por: Erselcan, T, et al.
Publicado: (2000)